Sangamo Therapeutics, Inc. (SGMOQ)
OTCMKTS · Delayed Price · Currency is USD
0.0675
-0.0025 (-3.57%)
Jul 21, 2026, 3:40 PM EST
Sangamo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 34.56 | 39.55 | 57.8 | 176.23 | 111.3 | 110.7 | |
Revenue Growth (YoY) | -45.80% | -31.57% | -67.20% | 58.34% | 0.54% | -6.34% |
Gross Profit | 34.56 | 39.55 | 57.8 | 176.23 | 111.3 | 110.7 |
Selling, General & Admin | 31.65 | 34.89 | 44.73 | 61.17 | 62.68 | 63.22 |
Research & Development | 113.23 | 112.67 | 111.52 | 234.06 | 249.9 | 230.82 |
Other Operating Expenses | - | 13.24 | 5.52 | 155.01 | - | - |
Total Operating Expenses | 144.88 | 160.79 | 161.77 | 450.24 | 312.58 | 294.04 |
Operating Income | -123.56 | -121.24 | -103.97 | -274.01 | -201.28 | -183.34 |
Interest Income | 1.29 | 1.3 | 1.51 | 11.1 | 9.43 | 5.35 |
Other Non-Operating Income (Expense) | -1.75 | -3.56 | 4.35 | - | - | - |
Total Non-Operating Income (Expense) | -0.46 | -2.26 | 5.86 | 11.1 | 9.43 | 5.35 |
Pretax Income | -124.02 | -123.5 | -98.11 | -262.9 | -191.85 | -177.99 |
Provision for Income Taxes | -0.69 | -0.57 | -0.17 | -5.07 | 0.43 | 0.31 |
Net Income | -123.33 | -122.93 | -97.94 | -257.83 | -192.28 | -178.3 |
Minority Interest in Earnings | - | - | - | - | - | -0.01 |
Net Income to Common | -123.33 | -122.93 | -97.94 | -257.83 | -192.28 | -178.29 |
Shares Outstanding (Basic) | 322 | 280 | 202 | 174 | 154 | 145 |
Shares Outstanding (Diluted) | 322 | 280 | 202 | 174 | 154 | 145 |
Shares Change (YoY) | 51.82% | 38.92% | 15.62% | 13.02% | 6.76% | 7.53% |
EPS (Basic) | -0.38 | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
EPS (Diluted) | -0.38 | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 |
Free Cash Flow | -90.46 | -97.31 | -67.41 | -246 | -243.8 | -256.53 |
Free Cash Flow Per Share | -0.28 | -0.35 | -0.33 | -1.41 | -1.58 | -1.77 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -357.55% | -306.53% | -179.88% | -155.48% | -180.85% | -165.62% |
Profit Margin | -356.89% | -310.81% | -169.45% | -146.30% | -172.76% | -161.06% |
FCF Margin | -261.76% | -246.03% | -116.62% | -139.59% | -219.05% | -231.73% |
EBITDA | -120.66 | -117.6 | -99.72 | -266.88 | -192.83 | -175.14 |
EBITDA Margin | -349.17% | -297.33% | -172.52% | -151.44% | -173.25% | -158.21% |
EBIT | -123.56 | -121.24 | -103.97 | -274.01 | -201.28 | -183.34 |
EBIT Margin | -357.55% | -306.53% | -179.88% | -155.48% | -180.85% | -165.62% |
Effective Tax Rate | 0.55% | 0.46% | 0.17% | 1.93% | -0.22% | -0.17% |